The impact of adding platinum on long-term outcomes in triple-negative breast cancer (TNBC) has not been definitively established. The controlled, single-centre, phase III study conducted by Tata Memorial Hospital in Mumbai, India evaluated the efficacy and toxicity of adding platinum to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. In this touchONCOLOGY interview, we speak with Dr Sudeep Gupta (Tata Memorial Hospital, Mumbai, India) who discusses the rationale for adding carboplatin to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer and gives an overview of his phase III study.
The abstract entitled ‘Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial’ was presented at San Antonio Breast Cancer Symposium (SABCS), 06–10, December, 2022.
Questions:
- What is the rationale for adding carboplatin to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer (TNBC)? (0:22)
- What were the methodology and eligibility criteria of your study evaluating this regimen? (1:26)
- What were the primary and secondary outcome measures and how well were they achieved? (3:25)
- What was the safety and tolerability of this regimen? (07:07)
- What will be the impact of these findings on the standard of care for TNBC? (8:10)
Disclosures: Sudeep Gupta has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen
Filmed as a highlight of SABCS 2022
Access more content on Breast Cancer
